Prognostic factors in advanced non-small cell lung cancer

Elevated serum levels of neuron specific enolase indicate poor prognosis

Tadashi Maeda, Hiroshi Ueoka, Masahiro Tabata, Katsuyuki Kiura, Takuo Shibayama, Kenichi Gemba, Nagio Takigawa, Akio Hiraki, Hideki Katayama, Mine Harada

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors. Methods: We analyzed prognostic factors in patients with advanced NSCLC who had been enrolled in clinical trials conducted by the Okayama Lung Cancer Study Group between 1978 and 1992 using two kinds of multivariate analysis, Cox's multivariate analysis and recursive partitioning and amalgamation (RPA) analysis. Results: The first analysis was performed on 261 patients using 28 variables. Performance status (PS), clinical stage, liver metastasis or serum albumin level was an independent prognostic factor by Cox's analysis. In the second analysis performed on 128 patients having data on neuron specific enolase (NSE), NSE was the most important prognostic factor. Using the RPA method, three subgroups with significantly different survival potentials were defined. Among them, patients with normal serum NSE levels and good PS were found to obtain a markedly favorable prognosis [median survival time (MST) 22.1 months, 3-year survival rate 42.9%], whereas the survival of patients with elevated serum NSE levels and bone metastasis was extremely short (MST 4.7 months, 3-year survival rate 0%). Conclusions: These results indicate that analysis of prognostic factors including serum levels of NSE is useful for predicting the survival of patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)534-541
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume30
Issue number12
Publication statusPublished - 2000

Fingerprint

Phosphopyruvate Hydratase
Non-Small Cell Lung Carcinoma
Serum
Survival
Multivariate Analysis
Survival Rate
Neoplasm Metastasis
Serum Albumin
Statistical Factor Analysis
Lung Neoplasms
Clinical Trials
Bone and Bones
Drug Therapy
Liver

Keywords

  • Neuron specific enolase
  • Non-small cell lung cancer
  • Prognostic factors
  • Recursive partitioning and amalgamation analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Prognostic factors in advanced non-small cell lung cancer : Elevated serum levels of neuron specific enolase indicate poor prognosis. / Maeda, Tadashi; Ueoka, Hiroshi; Tabata, Masahiro; Kiura, Katsuyuki; Shibayama, Takuo; Gemba, Kenichi; Takigawa, Nagio; Hiraki, Akio; Katayama, Hideki; Harada, Mine.

In: Japanese Journal of Clinical Oncology, Vol. 30, No. 12, 2000, p. 534-541.

Research output: Contribution to journalArticle

Maeda, Tadashi ; Ueoka, Hiroshi ; Tabata, Masahiro ; Kiura, Katsuyuki ; Shibayama, Takuo ; Gemba, Kenichi ; Takigawa, Nagio ; Hiraki, Akio ; Katayama, Hideki ; Harada, Mine. / Prognostic factors in advanced non-small cell lung cancer : Elevated serum levels of neuron specific enolase indicate poor prognosis. In: Japanese Journal of Clinical Oncology. 2000 ; Vol. 30, No. 12. pp. 534-541.
@article{45e6306c4f51460a9f55acde59094c2a,
title = "Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis",
abstract = "Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors. Methods: We analyzed prognostic factors in patients with advanced NSCLC who had been enrolled in clinical trials conducted by the Okayama Lung Cancer Study Group between 1978 and 1992 using two kinds of multivariate analysis, Cox's multivariate analysis and recursive partitioning and amalgamation (RPA) analysis. Results: The first analysis was performed on 261 patients using 28 variables. Performance status (PS), clinical stage, liver metastasis or serum albumin level was an independent prognostic factor by Cox's analysis. In the second analysis performed on 128 patients having data on neuron specific enolase (NSE), NSE was the most important prognostic factor. Using the RPA method, three subgroups with significantly different survival potentials were defined. Among them, patients with normal serum NSE levels and good PS were found to obtain a markedly favorable prognosis [median survival time (MST) 22.1 months, 3-year survival rate 42.9{\%}], whereas the survival of patients with elevated serum NSE levels and bone metastasis was extremely short (MST 4.7 months, 3-year survival rate 0{\%}). Conclusions: These results indicate that analysis of prognostic factors including serum levels of NSE is useful for predicting the survival of patients with advanced NSCLC.",
keywords = "Neuron specific enolase, Non-small cell lung cancer, Prognostic factors, Recursive partitioning and amalgamation analysis",
author = "Tadashi Maeda and Hiroshi Ueoka and Masahiro Tabata and Katsuyuki Kiura and Takuo Shibayama and Kenichi Gemba and Nagio Takigawa and Akio Hiraki and Hideki Katayama and Mine Harada",
year = "2000",
language = "English",
volume = "30",
pages = "534--541",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Prognostic factors in advanced non-small cell lung cancer

T2 - Elevated serum levels of neuron specific enolase indicate poor prognosis

AU - Maeda, Tadashi

AU - Ueoka, Hiroshi

AU - Tabata, Masahiro

AU - Kiura, Katsuyuki

AU - Shibayama, Takuo

AU - Gemba, Kenichi

AU - Takigawa, Nagio

AU - Hiraki, Akio

AU - Katayama, Hideki

AU - Harada, Mine

PY - 2000

Y1 - 2000

N2 - Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors. Methods: We analyzed prognostic factors in patients with advanced NSCLC who had been enrolled in clinical trials conducted by the Okayama Lung Cancer Study Group between 1978 and 1992 using two kinds of multivariate analysis, Cox's multivariate analysis and recursive partitioning and amalgamation (RPA) analysis. Results: The first analysis was performed on 261 patients using 28 variables. Performance status (PS), clinical stage, liver metastasis or serum albumin level was an independent prognostic factor by Cox's analysis. In the second analysis performed on 128 patients having data on neuron specific enolase (NSE), NSE was the most important prognostic factor. Using the RPA method, three subgroups with significantly different survival potentials were defined. Among them, patients with normal serum NSE levels and good PS were found to obtain a markedly favorable prognosis [median survival time (MST) 22.1 months, 3-year survival rate 42.9%], whereas the survival of patients with elevated serum NSE levels and bone metastasis was extremely short (MST 4.7 months, 3-year survival rate 0%). Conclusions: These results indicate that analysis of prognostic factors including serum levels of NSE is useful for predicting the survival of patients with advanced NSCLC.

AB - Background: Non-small cell lung cancer (NSCLC) is resistant to chemotherapy and prognosis of advanced NSCLC patients is considered to be dependent on various prognostic factors. Methods: We analyzed prognostic factors in patients with advanced NSCLC who had been enrolled in clinical trials conducted by the Okayama Lung Cancer Study Group between 1978 and 1992 using two kinds of multivariate analysis, Cox's multivariate analysis and recursive partitioning and amalgamation (RPA) analysis. Results: The first analysis was performed on 261 patients using 28 variables. Performance status (PS), clinical stage, liver metastasis or serum albumin level was an independent prognostic factor by Cox's analysis. In the second analysis performed on 128 patients having data on neuron specific enolase (NSE), NSE was the most important prognostic factor. Using the RPA method, three subgroups with significantly different survival potentials were defined. Among them, patients with normal serum NSE levels and good PS were found to obtain a markedly favorable prognosis [median survival time (MST) 22.1 months, 3-year survival rate 42.9%], whereas the survival of patients with elevated serum NSE levels and bone metastasis was extremely short (MST 4.7 months, 3-year survival rate 0%). Conclusions: These results indicate that analysis of prognostic factors including serum levels of NSE is useful for predicting the survival of patients with advanced NSCLC.

KW - Neuron specific enolase

KW - Non-small cell lung cancer

KW - Prognostic factors

KW - Recursive partitioning and amalgamation analysis

UR - http://www.scopus.com/inward/record.url?scp=0034488459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034488459&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 534

EP - 541

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

ER -